Folkestone Women's Health Project

RNS Number : 6318B

CareCapital Group plc

19 April 2012

 



19 April 2012

CARECAPITAL GROUP PLC

("CareCapital" or "the Company"

New Division to Focus on Women's Health

First Project Launched in Folkestone

CareCapital announces the formation of a new division to focus on the development of dedicated medical centres focused exclusively on women's health.  The first project will be based at the Company's Folkestone property.

The property, which is currently developed as a cosmetic dental surgery, will undergo an internal makeover to provide consulting rooms, a laboratory, luxurious waiting and resting areas and general administration space.  This will enable specialists in fields associated with women's health such as gynaecology, dermatology, breast care and nutrition to promote a holistic approach to healthcare in a private, attractive setting.  The inclusion of an onsite laboratory will mean pathology work can be processed quickly and results given during the patient's visit.

CareCapital, through its 75% owned subsidiary Oncotherapy Resources Limited, will be investigating the feasibility of offering the Xoft System® at the facility. The Xoft System uses an electronic X-ray source instead of a radioactive isotope to deliver radiation internally.  The low energy and rapid dose fall-off of the electronic source allow for treatment in rooms with reduced shielding requirements compared to conventional radiation therapy.  It is lightweight and mobile and can be moved easily between treatment locations.  This means that it can overcome the logistical challenges faced by many patients who may have to travel long distances to access conventional radiotherapy.   

The 8,500 sq ft Folkestone facility is spread over five floors with a substantial lobby/reception area and four floors of consultation and administration space.  It is anticipated that given the strength of the professionals and the environment created within the facility that this will become a "destination" health centre with visitors travelling from London and France.  Work on the new facility is currently underway with an estimated opening date of early 2013.

For further information, please visit www.carecapital.co.uk or contact:

Michael Sinclair, CEO	Sandy Jamieson	Jon Levinson	Simon Hudson, Kelsey Traynor
CareCapital Group Plc	Libertas Capital Corporate Finance Ltd (NOMAD & Joint Broker)	Rivington Street Corporate Finance (Joint Broker)	Tavistock Communications (Financial PR & IR)
020 3617 8727	020 7569 9650	020 7562 3357	020 7920 3150

About CareCapital

CareCapital recently announced a restructuring to reflect its strategy to reposition the Company primarily as an investor in, and provider of, advanced cancer treatments.  Current investments in medical centre development projects are to be transferred to the Company's wholly owned subsidiary - The Healthcare Property Company Limited - which will continue to progress existing schemes and expand through securing new medical centre projects in the UK.  This company will also provide property related support services to the wider CareCapital group. The Company also announced that it will be seeking shareholder authority at the earliest opportunity to change its name to Advanced Oncotherapy plc.

CareCapital specialises, as an innovative developer, in primary care real estate, particularly multi-occupancy premises that accommodate a variety of different, but often synergetic healthcare providers. This is particularly relevant at a time when the Government is intent on expanding primary care, bringing more services together under one roof and closer to patients in their own communities.  Working in partnership with local authorities, projects can involve significant urban regeneration, with mixed-use and mixed-economy developments incorporating housing, healthcare, childcare, retail and other appropriate facilities for the community.

CareCapital is also building a portfolio of innovative cancer treatment services to capture opportunities in the cancer diagnosis and treatment market, building on its 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its newly launched Oncotherapy Resources business focused on early stage breast cancer treatment.  Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK and which has secured planning approval for its first London based centre off Moorgate in the City of London, within easy access of a number of London's major hospitals.

-ends-

 

END

 

 

MSCBKFDQOBKDBQD